Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.63 |
| ▸ | PDE4A | P27815 | 3/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22471417 | 0.89 | ADORA2B (0.68) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL2119480 | 0.85 | ADORA2B (0.63) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL5463429 | 0.83 | ADORA2B (0.68) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL27552726 | 0.83 | ADORA2B (0.60) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL516014 | 0.83 | ADORA2B (0.72) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL8659000 | 0.82 | ADORA2B (0.59) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL25778327 | 0.81 | PDE4A (0.71) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL515570 | 0.80 | PDE4A (0.83) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL9293292 | 0.80 | PDE4A (0.62) | ADORA2BPDE4AADORA2APDE4BPDE4C | |
| SCHEMBL14985852 | 0.79 | LMNA (0.58) | ADORA2BPDE4AADORA2APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470805-B2 | Processes for preparing piperazinium salts of KMUP and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | disclosed |
| WO-2012031445-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (CN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-06-09 | — | — | US | disclosed |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | KAOHSIUNG MEDICAL UNIVERSITY | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | U2SURP, RRP15, KYNU | ADORA2B 1268/4885PDE4A 550/4885ADORA2A 969/4885 |
| US-20110118464-A1 | HALOGENATED XANTHINE DERIVATIVES AND PRECURSORS THEREOF FOR ANTI-CANCER AND ANTI-METASTASIS ACTIVITY AND PREPARING METHOD THEREOF | TK1, XDH, KYAT1 | ADORA2B 2865/4885PDE4A 920/4885ADORA2A 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.